输注供者来源CD8+记忆T细胞治疗异基因造血细胞移植后复发
在小鼠模型显示CD8+CD44hi记忆T细胞可清除恶性细胞而不诱导移植物抗宿主病(GVHD)的基础上,这项研究评估了输注新鲜分离纯化的供者表型CD8+记忆T细胞至异基因造血细胞移植(HCT)后复发成人的可行性与安全性。15例患者接受递增剂量(1×10^6、5×10^6或10×10^6细胞/kg)输注,未发生输注不良事件或剂量限制性毒性,1例发生GVHD(2级肝脏);10例(67%)维持或达到缓解至少3个月,中位无事件生存期4.9个月,中位总生存期19.6个月。
要点
- 供者表型CD8+记忆T细胞经CD45RA去除后CD8+富集可新鲜分离纯化,平均产量38.1%、纯度92.8%。
- 15例异基因HCT后复发患者接受递增剂量CD8+记忆T细胞输注,无输注不良事件或剂量限制性毒性,1例发生2级肝脏GVHD。
- 10例(67%)维持或达到缓解至少3个月(7例完全缓解、1例部分缓解、2例疾病稳定),中位无事件生存期4.9个月,中位总生存期19.6个月。
核心结论
- 供者表型CD8+记忆T细胞的采集与富集可行、耐受良好,作为经处理的供者淋巴细胞输注用于HCT后复发患者时GVHD发生率低。
研究设计与样本
- 评估新鲜分离纯化供者表型CD8+记忆T细胞输注至异基因HCT后复发成人的可行性与安全性研究,15例患者接受递增剂量(1×10^6、5×10^6或10×10^6细胞/kg)输注。
- 表型CD8+记忆T细胞在未动员供者单采后采用CD45RA去除继以CD8+富集的串联免疫磁珠选择策略分离。
- 13例在CD8+记忆T细胞输注前接受减细胞治疗,9例在输注时有活动性疾病。
主要发现
- CD8+记忆T细胞输注的平均产量和纯度分别为38.1%和92.8%,>90%具有CD8+效应记忆表型、细胞因子表达和分泌谱。
- 未发生输注不良事件或剂量限制性毒性;1例患者发生GVHD(2级肝脏)。
- 10例患者(67%)在输注后至少3个月维持或达到缓解(7例完全缓解、1例部分缓解、2例疾病稳定);缓解者中4例在输注时有活动性疾病。
- 自输注起中位随访328天(范围118-1328天),中位无事件生存期为4.9个月(95%CI 1-19.3个月),中位总生存期为19.6个月(95%CI 5.6个月至未达到)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Murine models showed that CD8+CD44hi memory T (TM) cells could eradicate malignant cells without inducing graft-versus-host disease (GVHD). We evaluated the feasibility and safety of infusing freshly isolated and purified donor-derived phenotypic CD8+ TM cells into adults with disease relapse after allogeneic hematopoietic cell transplantation (HCT). Phenotypic CD8 TM cells were isolated after unmobilized donor apheresis using a tandem immunomagnetic selection strategy of CD45RA depletion followed by CD8+ enrichment. Fifteen patients received CD8+ TM cells at escalating doses (1 × 106, 5 × 106, or 10 × 106 cells per kg). Thirteen received cytoreduction before CD8+ TM cell infusion, and 9 had active disease at the time of infusion. Mean yield and purity of the CD8+ TM infusion were 38.1% and 92.8%, respectively; >90% had CD8+ T effector memory phenotype, cytokine expression, and secretion profile. No adverse infusional events or dose-limiting toxicities occurred; GVHD developed in 1 patient (grade 2 liver). Ten patients (67%) maintained or achieved response (7 complete response, 1 partial response, 2 stable disease) for at least 3 months after infusion; 4 of the responders had active disease at the time of infusion. With a median follow-up from infusion of 328 days (range, 118-1328 days), median event-free survival and overall survival were 4.9 months (95% confidence interval [CI], 1-19.3 months) and 19.6 months (95% CI, 5.6 months to not reached), respectively. Collection and enrichment of phenotypic CD8+ TM cells is feasible, well tolerated, and associated with a low incidence of GVHD when administered as a manipulated infusion of donor lymphocytes in patients who have relapsed after HCT. This trial was registered at www.clinicaltrials.gov as #NCT01523223.
引用
- Muffly L, Sheehan K, Armstrong R, et al. Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2018. PMID: 29572391. doi:10.1182/bloodadvances.2017012104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。